|Bid||0.00 x 3200|
|Ask||0.00 x 2900|
|Day's Range||2.9650 - 3.4650|
|52 Week Range||2.9650 - 3.4650|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Legendary investor Seth Klarman (Trades, Portfolio) disclosed Thursday that his long-term stake in kidney care company Keryx Biopharmaceuticals (KERX) closed as it converted into a stake in Akebia Therapeutics (AKBA) upon the merger of the two companies. Warning! GuruFocus has detected 2 Warning Signs with TBPH.
Akebia Therapeutics Inc (NASDAQ: AKBA ) announced shareholder approval this week for its merger with Keryx Biopharmaceuticals (NASDAQ: KERX ). The Analyst Analyst Reni Benjamin of Raymond James maintains ...
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc. Separately today, Akebia announced that its stockholders voted to approve the share issuance proposal relating to the merger with Keryx at a special meeting of Akebia stockholders.
Keryx Biopharma (KERX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommends Keryx stockholders vote “FOR” the merger and the proposals relating to the proposed merger with Akebia Therapeutics, Inc. (AKBA) at the Special Meeting of Keryx stockholders to be held on December 11, 2018.
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Akebia Therapeutics, Inc. (AKBA), and Keryx Biopharmaceuticals, Inc. (KERX) today announced that Adrian Adams will serve as the Chairperson of the Akebia Board of Directors, effective upon completion of the proposed merger of Akebia and Keryx. “I am excited and honored to serve as the Chairperson of the combined company after the merger,” said Mr. Adams. “Following the merger, Akebia will be a fully integrated, leading renal company with the potential to deliver an all oral treatment approach for patients with anemia due to chronic kidney disease.
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Keryx Biopharmaceuticals, Inc. ("Keryx" ...
NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the District of Delaware, Case No.1:18-cv-01589-LPS, on behalf of public common shareholders of Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (KERX) who held Keryx securities on the record date October 22, 2018 (the "Class Period"), and have been harmed by Keryx and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to Akebia Therapeutics (the "Proposed Transaction"). Under the terms of the Merger Agreement, Keryx shareholders are only anticipated to receive 0.37433 shares of Akebia for each share of Keryx common stock they hold (the "Merger Consideration").
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
The Boston-based company said it had a loss of 14 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...
NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union ...
NEW YORK, NY / ACCESSWIRE / October 8, 2018 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York ...
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors (“Board”) of Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (NASDAQ CM: KERX) related to the Company’s entry into an agreement to merge with Akebia Therapeutics, Inc. (“Akebia”) (NASDAQ GM: AKBA) in a transaction announced on June 28, 2018 (the “Proposed Transaction”). On June 28, 2018, the Board caused Keryx to enter into an agreement and plan of merger (the “Merger Agreement”) with Akebia. Pursuant to the terms of the Merger Agreement, shareholders of Keryx will receive 0.37433 common shares of Akebia for each share of Keryx they own.
NEW YORK , Oct. 1, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City ...